The University of Iowa
The University of Iowa News Services Home News Releases UI in the News Subscribe to UI News Contact Us

 

CONTACT: Bruce Wheaton
UI Research Foundation
Roman Terrill, J.D., Integrated DNA (319) 626-8451
Phone: (319) 335-4546

Release: Feb. 28, 2002

UI Research Foundation earns royalty payment from Integrated DNA Technologies

         Integrated DNA Technologies, Inc. (IDT), announced today a    significant royalty payment to the University of Iowa Research Foundation (UIRF) required under a license agreement covering two patented DNA based technologies invented by the company's president and CEO, Dr. Joseph A. Walder, while he was a University of Iowa professor of  biochemistry.

            IDT, which now employs more than 300 people, got its commercial start in the university's business incubator, the Technology Innovation Center (TIC), on the UI Oakdale Campus. The payment of approximately $175,000 was made for the development of technologies invented nearly two decades ago in UI research laboratories.

            "IDT is very pleased to share with the University of Iowa Research Foundation the commercial success of these two technologies," said Walder. "We are hopeful that IDT and the UIRF will continue to enjoy further success over the life of these valuable patents. IDT is particularly pleased to be working with the UIRF, which shares a common mission with IDT—fostering innovation in basic research and development in the life sciences. IDT intends to make these technologies more accessible to academic researchers and their students, and we trust our various partners will make the long-felt promise of these technologies in the diagnostic and therapeutic settings a near-term reality."

            The patented technologies relate to the use of nucleic acids (DNA) in research and clinical applications. One technology, called catalytic hybdrization amplification, allows researchers or clinicians to detect the presence of a nucleic acid sequence in a sample by designing a DNA probe that is cleaved when it identifies its target sequence. This technology has been used clinically as a diagnostic methodology, and was sub-licensed to a Canadian biomedical company.

            The second technology, in the field of "antisense," allows researchers to determine the function of particular genes in an organism by using specific DNA fragments to inhibit the activity of the targeted genes in cells. The technology has proven to be a very valuable research tool helping to unravel many of the functions of the enormous number of genes recently identified under the Human Genome Project. In addition, antisense technology is being developed by pharmaceutical companies, which use antisense DNA as a therapeutic means to inhibit the activity of genes that cause certain diseases.

            The University of Iowa Research Foundation filed patent applications on the two technologies in 1987 and 1988, and later exclusively licensed those patent applications to Integrated DNA Technologies, Inc, which was then a start-up company at the University's Technology Innovation Center on the UI Oakdale Campus.  IDT funded the prosecution of the patent applications over the course of the next 13 years. IDT was able to successfully sublicense the resulting patents to various companies in the genomics and pharmaceutical industries.

            Bruce Wheaton, director of the University of Iowa Research Foundation and the Technology Innovation Center, added that "The University is proud to be affiliated with a company dedicated to bringing cutting edge research technologies into laboratories and classrooms around the world. We congratulate IDT because their hard work has transformed a start-up company with fewer than five workers into one of the area's most significant employers." He also noted that IDT's recent payment for technologies invented nearly two decades ago illustrates the tremendous time and costs often associated with commercializing such inventions.

            Said Wheaton, "We hope that as a result of IDT's efforts, researchers and students at the University of Iowa and elsewhere will be better equipped to investigate the rich information made available by the Human Genome Project."

            Integrated DNA Technologies, Inc., an Iowa-based biotechnology company, is a major force in advancing biomedical research as both a supplier of custom oligonucleotides and a developer of innovative new biotechnology. As a leading manufacturer of synthetic DNA/RNA, IDT provides products to over 14,000 customers worldwide. With a comprehensive sales team, IDT has strong presence in both the academic and corporate marketplace. IDT's research division is committed to improving nucleic acid synthesis technology and developing new applications for DNA and RNA based compounds. IDT's advanced synthesis group combines expertise in chemistry, molecular biology, information systems and engineering to produce and purify complex nucleic acids of all kinds. Integrated DNA Technologies is located near major university, medical and research centers in Coralville, Iowa with offices in the Chicago area. IDT is dedicated to being the world's leader in innovation and precision in nucleic acid synthesis.